These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 21046170)
1. [Experiences of cancer patients with breakthrough pain and pharmacological treatments]. Bertram L; Stiel S; Elsner F; Radbruch L; Davies A; Nauck F; Alt-Epping B Schmerz; 2010 Dec; 24(6):605-12. PubMed ID: 21046170 [TBL] [Abstract][Full Text] [Related]
2. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Davies A; Zeppetella G; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M; Buchanan A Eur J Pain; 2011 Aug; 15(7):756-63. PubMed ID: 21251860 [TBL] [Abstract][Full Text] [Related]
3. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176 [TBL] [Abstract][Full Text] [Related]
4. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study. Hagen NA; Fisher K; Stiles C J Palliat Med; 2007 Apr; 10(2):331-7. PubMed ID: 17472503 [TBL] [Abstract][Full Text] [Related]
5. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Brogan SE; Winter NB; Okifuji A Reg Anesth Pain Med; 2015; 40(4):369-75. PubMed ID: 25923819 [TBL] [Abstract][Full Text] [Related]
6. A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain. Bedard G; Hawley P; Zhang L; Slaven M; Gagnon P; Bisland S; Bennett M; Tardif F; Chow E Support Care Cancer; 2013 Sep; 21(9):2557-63. PubMed ID: 23636647 [TBL] [Abstract][Full Text] [Related]
7. Management of breakthrough pain due to cancer. Simmonds MA Oncology (Williston Park); 1999 Aug; 13(8):1103-8; discussion 1110, 1113-4. PubMed ID: 10499244 [TBL] [Abstract][Full Text] [Related]
8. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786 [TBL] [Abstract][Full Text] [Related]
9. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084 [TBL] [Abstract][Full Text] [Related]
10. Intranasal sufentanil for cancer-associated breakthrough pain. Good P; Jackson K; Brumley D; Ashby M Palliat Med; 2009 Jan; 23(1):54-8. PubMed ID: 19144765 [TBL] [Abstract][Full Text] [Related]
11. Breakthrough cancer pain: a comparison of surveys with European and Canadian patients. Bedard G; Davies A; McDonald R; Hawley P; Buchanan A; Popovic M; Wong E; Chow E Support Care Cancer; 2015 Mar; 23(3):791-6. PubMed ID: 25193599 [TBL] [Abstract][Full Text] [Related]
13. Breakthrough cancer pain: an observational study of 1000 European oncology patients. Davies A; Buchanan A; Zeppetella G; Porta-Sales J; Likar R; Weismayr W; Slama O; Korhonen T; Filbet M; Poulain P; Mystakidou K; Ardavanis A; O'Brien T; Wilkinson P; Caraceni A; Zucco F; Zuurmond W; Andersen S; Damkier A; Vejlgaard T; Nauck F; Radbruch L; Sjolund KF; Stenberg M J Pain Symptom Manage; 2013 Nov; 46(5):619-28. PubMed ID: 23523361 [TBL] [Abstract][Full Text] [Related]
14. [Pain therapy in cancer patients]. Aulmann C; Hainsch-Müller I MMW Fortschr Med; 2013 Apr; 155(7):64-8. PubMed ID: 23668181 [No Abstract] [Full Text] [Related]
15. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182 [TBL] [Abstract][Full Text] [Related]
16. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Kleeberg UR; Filbet M; Zeppetella G Pain Pract; 2011; 11(2):185-90. PubMed ID: 20807349 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study. Zheng S; He L; Yang X; Li X; Yang Z Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770 [TBL] [Abstract][Full Text] [Related]
18. [Factors associated with refractory cancer pain]. Piguet V; Desmeules J; Allaz AF; Kondo Oestreicher M; Dayer P Schweiz Med Wochenschr; 1998 Feb; 128(6):208-11. PubMed ID: 9540143 [TBL] [Abstract][Full Text] [Related]
19. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. Portenoy RK; Bruns D; Shoemaker B; Shoemaker SA J Opioid Manag; 2010; 6(2):109-16. PubMed ID: 20481175 [TBL] [Abstract][Full Text] [Related]